Back to Search
Start Over
Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
- Source :
-
International urology and nephrology [Int Urol Nephrol] 1993; Vol. 25 (4), pp. 351-7. - Publication Year :
- 1993
-
Abstract
- Thirteen patients with advanced urothelial transitional cell carcinoma were treated with methotrexate, vinblastine, adriamycin and cisplatin combination. No complete remissions were achieved in patients with disseminated diseases; only three out of five patients (60%) with localized tumours in the bladder or perivesical space responded completely. Localized tumour recurrences in the bladder occurred in two of three complete responders at the ninth and tenth months after chemotherapy. Four patients died during or after chemotherapy: one from disease progression and the remainder from chemotherapy complications. Authors conclude that, although 23% complete and 30.8% partial remissions were achieved with the MVAC chemotherapy, strict toxicity monitoring and careful selection of patients are essential because of its non-negligible complications.
- Subjects :
- Aged
Antineoplastic Combined Chemotherapy Protocols adverse effects
Carcinoma, Transitional Cell pathology
Cisplatin administration & dosage
Doxorubicin administration & dosage
Female
Follow-Up Studies
Humans
Male
Methotrexate administration & dosage
Middle Aged
Neoplasm Recurrence, Local pathology
Neoplasm Staging
Remission Induction
Urinary Bladder Neoplasms pathology
Vinblastine administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Transitional Cell drug therapy
Urinary Bladder Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0301-1623
- Volume :
- 25
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- International urology and nephrology
- Publication Type :
- Academic Journal
- Accession number :
- 8276565